Amedeo Smart

Free Medical Literature Service


 

Amedeo

Multiple Sclerosis

  Free Subscription

Articles published in
Neurology
    October 2021
  1. TINTORE M, Cobo-Calvo A, Carbonell P, Arrambide G, et al
    Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome.
    Neurology. 2021;97:e1641-e1652.
    >> Share

  2. AA HOGLUND RA, Meyer HE, Stigum H, Torkildsen O, et al
    Association of Body Mass Index in Adolescence and Young Adulthood and Long-term Risk of Multiple Sclerosis: A Population-Based Study.
    Neurology. 2021 Oct 25. pii: WNL.0000000000012957.
    >> Share

  3. KALINCIK T, Tremlett H, Ascherio A
    High BMI In Youths as a Modifiable Risk Factor for Multiple Sclerosis: Weighing Up the Evidence.
    Neurology. 2021 Oct 25. pii: WNL.0000000000012966.
    >> Share

  4. JANDRIC D, Lipp I, Paling D, Rog D, et al
    Mechanisms of Network Changes in Cognitive Impairment in Multiple Sclerosis.
    Neurology. 2021 Oct 14. pii: WNL.0000000000012834.
    >> Share

  5. SIMPSON-YAP S, De Brouwer E, Kalincik T, Rijke N, et al
    Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Neurology. 2021 Oct 5. pii: WNL.0000000000012753.
    >> Share

  6. KILLESTEIN J, Schoonheim MM, Voskuhl RR
    B-Cell Depletion and COVID-19 Severity in Multiple Sclerosis: Remaining Challenges.
    Neurology. 2021 Oct 5. pii: WNL.0000000000012754.
    >> Share

  7. BONACCHI R, Meani A, Pagani E, Marchesi O, et al
    Association of Age at Onset With Gray Matter Volume and White Matter Microstructural Abnormalities in People With Multiple Sclerosis.
    Neurology. 2021 Oct 4. pii: WNL.0000000000012869.
    >> Share

  8. HACOHEN Y, Eshaghi A
    Multiple Sclerosis in Children and Adults: Does Age Matter?
    Neurology. 2021 Oct 4. pii: WNL.0000000000012866.
    >> Share

    September 2021
  9. MERLO D, Stankovich J, Bai C, Kalincik T, et al
    Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2021 Sep 23. pii: WNL.0000000000012850.
    >> Share

  10. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
    Colorectal Cancer Survival in Multiple Sclerosis: A Matched Cohort Study.
    Neurology. 2021 Sep 15. pii: WNL.0000000000012634.
    >> Share

  11. TOBIN O
    Early Diagnosis and Treatment is Associated With Improved Outcomes in Patients With Multiple Sclerosis.
    Neurology. 2021 Sep 14. pii: WNL.0000000000012738.
    >> Share

  12. GOLDSCHMIDT C, Fox RJ
    Relationship Between Serum Neurofilament Light and Multiple Sclerosis Disability Progression: Clear as Mud.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012755.
    >> Share

  13. TOBIN WO, Kalinowska-Lyszczarz A, Weigand SD, Guo Y, et al
    Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012782.
    >> Share

  14. BRIDEL C, Leurs CE, van Lierop ZY, van Kempen ZL, et al
    Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012752.
    >> Share

  15. YEH EA, Bourdette D, Wiendl H
    Longer-Term Safety of B-Cell Therapy With Ocrelizumab in Multiple Sclerosis.
    Neurology. 2021 Sep 2. pii: WNL.0000000000012716.
    >> Share

  16. HAUSER SL, Kappos L, Montalban X, Craveiro L, et al
    Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.
    Neurology. 2021 Sep 2. pii: WNL.0000000000012700.
    >> Share

  17. PALLADINO R, Chataway J, Majeed A, Marrie RA, et al
    Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality: A Population-Based Matched Cohort Study.
    Neurology. 2021 Sep 1. pii: WNL.0000000000012610.
    >> Share

  18. SALTER A
    Assessment of Biological Interactions Between MS Status and Depression for Mortality.
    Neurology. 2021 Sep 1. pii: WNL.0000000000012615.
    >> Share

    August 2021
  19. RICE J, Xiang XM
    Comparing the Effectiveness of Therapies in People With Secondary Progressive Multiple Sclerosis.
    Neurology. 2021;97:e972-e974.
    >> Share

  20. DOBSON R, Salter A
    Differing Impact of Disease-Modifying Therapy on Relapse and Progression: Time to Consider Inflammation and Neuroprotection Separately?
    Neurology. 2021;97:407-408.
    >> Share

  21. KOCH MW, Mostert JP, Wolinsky JS, Lublin FD, et al
    Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2021 Aug 25. pii: WNL.0000000000012690.
    >> Share

  22. KOCH MW, Mostert J, Zhang Y, Wolinsky JS, et al
    Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.
    Neurology. 2021 Aug 10. pii: WNL.0000000000012603.
    >> Share

    July 2021
  23. SECHI E, Krecke KN, Messina SA, Buciuc M, et al
    Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.
    Neurology. 2021 Jul 14. pii: WNL.0000000000012467.
    >> Share

  24. NICHOLAS RS, Rhone EE, Mariottini A, Silber E, et al
    Autologous Haematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: a Real-world Case Series.
    Neurology. 2021 Jul 12. pii: WNL.0000000000012449.
    >> Share

  25. HACOHEN Y, Kerr W, Waters P
    Intrathecal Production of MOG-IgG: Highlighting the Need for CSF Testing in Clinical Practice.
    Neurology. 2021;97:12-13.
    >> Share

    June 2021
  26. GRAY-RONCAL K, Fitzgerald K, Ryerson LZ, Charvet L, et al
    Association of Disease Severity and Socioeconomic Status in Black and White Americans With Multiple Sclerosis.
    Neurology. 2021 Jun 30. pii: WNL.0000000000012362.
    >> Share

  27. ROOS I, Leray E, Casey R, Horakova D, et al
    Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis.
    Neurology. 2021 Jun 30. pii: WNL.0000000000012354.
    >> Share

  28. HUISKAMP M, Eijlers AJC, Broeders TAA, Pasteuning J, et al
    Longitudinal Network Changes and Conversion to Cognitive Impairment in Multiple Sclerosis.
    Neurology. 2021 Jun 7. pii: WNL.0000000000012341.
    >> Share

  29. PREZIOSA P, Schoonheim MM
    Ongoing Axonal Injury in Chronic Active Lesions in Multiple Sclerosis: In-Vivo Quantification Using Serum Neurofilament.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012331.
    >> Share

  30. CAMPBELL CREE BA, Arnold DL, Chataway J, Chitnis T, et al
    Secondary Progressive Multiple Sclerosis: New Insights.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012323.
    >> Share

  31. MAGGI P, Kuhle J, Schadelin S, van der Meer F, et al
    Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012326.
    >> Share

    May 2021
  32. ROLLOT F, Fauvernier M, Uhry Z, Vukusic S, et al
    Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort.
    Neurology. 2021 May 19. pii: WNL.0000000000012224.
    >> Share

  33. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
    Breast Cancer Survival in Multiple Sclerosis: A Matched Cohort Study.
    Neurology. 2021 May 19. pii: WNL.0000000000012127.
    >> Share

  34. TOOSY AT, Kapur K, Nair KV
    Is OCT a Viable Tool to Monitor Disease-Modifying Treatments in RRMS Yet?
    Neurology. 2021;96:927-928.
    >> Share


  35. Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
    Neurology. 2021 May 4. pii: WNL.0000000000011825.
    >> Share

  36. FOX RJ, Kryscio RJ
    A New Way to Identify Promising Therapies for Progressive Multiple Sclerosis.
    Neurology. 2021;96:833-834.
    >> Share

  37. KOCH MW, Sage K, Kaur S, Kim J, et al
    Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial.
    Neurology. 2021;96:e2313-e2322.
    >> Share

  38. BAR-OR A, Herman A, Stokmaier D
    Author Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:870.
    >> Share

  39. HAHN N
    Reader Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:870.
    >> Share

  40. SIEGLER JE, Galetta S
    Editors' Note: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:869.
    >> Share

    April 2021
  41. DUBESSY AL, Tezenas du Montcel S, Viala F, Assouad R, et al
    Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2021 Apr 30. pii: WNL.0000000000012120.
    >> Share

  42. LEAVITT VM, Dobson R, Svennigsson A
    Perinatal Depression and Anxiety in Multiple Sclerosis: Treatable Distress.
    Neurology. 2021 Apr 28. pii: WNL.0000000000012101.
    >> Share

  43. SALAVISA M, Serrazina F, Pires P, Correia AS, et al
    Teaching Video NeuroImages: Infratentorial Multiple Sclerosis Relapse Presenting as Continuous Hemifacial Myokymia.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012052.
    >> Share

  44. GASPERI C, Hapfelmeier A, Daltrozzo T, Schneider A, et al
    Systematic Assessment of Medical Diagnoses Preceding the First Diagnosis of Multiple Sclerosis.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012074.
    >> Share

  45. SOLOMON AJ, Ascherio A
    Early Diagnosis of Multiple Sclerosis: Further Evidence for Missed Opportunity.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012087.
    >> Share


  46. Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis.
    Neurology. 2021 Apr 23. pii: WNL.0000000000012021.
    >> Share

  47. EID K, Torkildsen OF, Aarseth J, Flemmen HO, et al
    Perinatal Depression and Anxiety in Women with Multiple Sclerosis: A Population-Based Cohort Study.
    Neurology. 2021 Apr 21. pii: WNL.0000000000012062.
    >> Share

  48. YEH WZ, Widyastuti PA, Van der Walt A, Stankovich J, et al
    Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
    Neurology. 2021 Apr 20. pii: WNL.0000000000012084.
    >> Share

  49. LAMBE J, Risher H, Filippatou AG, Murphy OC, et al
    Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis.
    Neurology. 2021 Apr 7. pii: WNL.0000000000011933.
    >> Share

    March 2021
  50. POIRION E, Tonietto M, Lejeune FX, Ricigliano VAG, et al
    Structural and Clinical Correlates of a Periventricular Gradient of Neuroinflammation in Multiple Sclerosis.
    Neurology. 2021 Mar 18. pii: WNL.0000000000011700.
    >> Share

  51. LAMBE J, Fitzgerald KC, Murphy OC, Filippatou AG, et al
    Association of Spectral-Domain OCT With Long-term Disability Worsening in Multiple Sclerosis.
    Neurology. 2021 Mar 2. pii: WNL.0000000000011788.
    >> Share

  52. VILLOSLADA P, Galetta SL, Toosy A
    Seeing the Finish Line: Can Baseline OCT Values Predict Long-Term Disability and Therapeutic Management in Multiple Sclerosis?
    Neurology. 2021 Mar 2. pii: WNL.0000000000011793.
    >> Share

  53. BANSAL P, Paul BS, Singh G
    Multiple Sclerosis Relapse Presenting As Sensorineural Hearing Loss.
    Neurology. 2021 Mar 2. pii: WNL.0000000000011796.
    >> Share

    February 2021
  54. KALAITZIDIS G, Calabresi PA
    Is Cerebrospinal Fluid Responsible for Innate Immune Cell Activation and Neurotoxicity in Multiple Sclerosis?
    Neurology. 2021 Feb 15. pii: WNL.0000000000011694.
    >> Share


  55. Evaluation of Multiple Sclerosis Disability Outcome Measures Using Pooled Clinical Trial Data.
    Neurology. 2021 Feb 12. pii: WNL.0000000000011677.
    >> Share

    January 2021
  56. ALPING P, Burman J, Lycke J, Frisell T, et al
    Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Non-induction Therapies for Multiple Sclerosis.
    Neurology. 2021 Jan 29. pii: WNL.0000000000011545.
    >> Share

  57. BROWNLEE WJ, Galetta S
    Optic Nerve in Multiple Sclerosis Diagnostic Criteria: An Aye to the Eyes?
    Neurology. 2021;96:139-140.
    >> Share

  58. SORMANI MP, Tur C, Barkhof F
    Ibudilast: A Paradigm Shift for Progressive Multiple Sclerosis?
    Neurology. 2021;96:141-142.
    >> Share

  59. BOFFA G, Massacesi L, Inglese M, Mariottini A, et al
    Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
    Neurology. 2021 Jan 20. pii: WNL.0000000000011461.
    >> Share

  60. LEAVITT VM, Rocca M
    Siponimod for Cognition in Secondary Progressive Multiple Sclerosis: Thinking Through the Evidence.
    Neurology. 2021;96:91-92.
    >> Share

  61. ROCCA MA, Valsasina P, Meani A, Gobbi C, et al
    Association of Gray Matter Atrophy Patterns with Clinical Phenotype and Progression in Multiple Sclerosis.
    Neurology. 2021 Jan 13. pii: WNL.0000000000011494.
    >> Share

  62. BOVIS F, Kalincik T, Lublin F, Cutter G, et al
    Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.
    Neurology. 2021;96:e214-e227.
    >> Share

  63. SHAH S, Klassen BT, Flanagan EP
    Paroxysmal Dysarthria-Ataxia in Multiple Sclerosis.
    Neurology. 2021 Jan 5. pii: WNL.0000000000011498.
    >> Share

  64. KALINCIK T, Sormani MP, Tur C
    Has the Time Come to Revisit Our Standard Measures of Disability Progression in Multiple Sclerosis?
    Neurology. 2021;96:12-13.
    >> Share

    December 2020
  65. KALINCIK T, Diouf I, Sharmin S, Malpas C, et al
    Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
    Neurology. 2020 Dec 28. pii: WNL.0000000000011242.
    >> Share


  66. The 2013 clinical course descriptors for multiple sclerosis: A clarification.
    Neurology. 2020 Dec 22. pii: WNL.0000000000011198.
    >> Share

  67. BENEDICT RHB, Tomic D, Cree BA, Fox R, et al
    Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses.
    Neurology. 2020 Dec 16. pii: WNL.0000000000011275.
    >> Share

  68. VIDAL-JORDANA A, Rovira A, Arrambide G, Otero-Romero S, et al
    Optic nerve region in multiple sclerosis diagnosis: the utility of visual evoked potentials.
    Neurology. 2020 Dec 16. pii: WNL.0000000000011339.
    >> Share

  69. NAISMITH RT, Bermel RA, Coffey CS, Goodman AD, et al
    Effects of ibudilast on MRI measures in the phase 2 SPRINT-MS study.
    Neurology. 2020 Dec 2. pii: WNL.0000000000011314.
    >> Share

  70. LANGESKOV-CHRISTENSEN M, Grondahl Hvid L, Nygaard MKE, Ringgaard S, et al
    Efficacy of high-intensity aerobic exercise on brain MRI measures in multiple sclerosis.
    Neurology. 2020 Dec 1. pii: WNL.0000000000011241.
    >> Share

  71. BINZER S, Manouchehrinia A, Hillert J
    Author response: Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.
    Neurology. 2020;95:1026.
    >> Share

  72. BSTEH G, Berger T
    Reader response: Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.
    Neurology. 2020;95:1025-1026.
    >> Share

  73. GANESH A, Galetta S
    Editors' note: Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.
    Neurology. 2020;95:1025.
    >> Share

    November 2020
  74. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
    Cancer incidence and mortality rates in multiple sclerosis: A matched cohort study.
    Neurology. 2020 Nov 25. pii: WNL.0000000000011219.
    >> Share

    October 2020
  75. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    Reliability of outcome measures in clinical trials in secondary progressive multiple sclerosis.
    Neurology. 2020 Oct 26. pii: WNL.0000000000011123.
    >> Share

  76. KLEIN DA COSTA B, Brant de Souza Melo R, Passos GRD, Gomes Meneses Sevilha Castro D, et al
    Unraveling B lymphocytes in CNS inflammatory diseases: Distinct mechanisms and treatment targets.
    Neurology. 2020;95:733-744.
    >> Share

    September 2020
  77. MOCCIA M, van de Pavert S, Eshaghi A, Haider L, et al
    Pathological correlates of the magnetization transfer ratio in multiple sclerosis.
    Neurology. 2020 Sep 16. pii: WNL.0000000000010909.
    >> Share

  78. ROTSTEIN DL, Yeh EA
    Could wider social networks prevent disability in MS and other neurologic disorders?
    Neurology. 2020;95:463-464.
    >> Share

    August 2020
  79. WALLIN MT
    Initial highly effective therapy for MS: A strong start.
    Neurology. 2020;95:e1114-e1116.
    >> Share

  80. RUPRECHT K, Pfuhl C, Oechtering J
    Author response: Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis.
    Neurology. 2020;95:277-278.
    >> Share

  81. ALCALA C, Perez-Miralles FC, Gil-Perotin S, Casanova B, et al
    Reader response: Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis.
    Neurology. 2020;95:277.
    >> Share

  82. SIEGLER JE 3RD, Galetta S
    Editors' note: Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis.
    Neurology. 2020;95:276.
    >> Share

  83. OUTTERYCK O, Lopes R, Drumez E, Labreuche J, et al
    Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndrome.
    Neurology. 2020;95:e733-e744.
    >> Share

  84. VAN KEMPEN ZLE, Hoogervorst ELJ, Wattjes MP, Kalkers NF, et al
    Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
    Neurology. 2020;95:e745-e754.
    >> Share

  85. DIXON L, Shah S
    Teaching NeuroImages: Hypertrophic polyneuropathy.
    Neurology. 2020;95:e779-e780.
    >> Share

  86. LEVIN SN, Riley CS, Dhand A, White CC, et al
    Association of Social Network Structure and Physical Function in Patients With Multiple Sclerosis.
    Neurology. 2020 Aug 7. pii: WNL.0000000000010460.
    >> Share

  87. NELSON LM, Bourdette D
    Two decades of research: Time to incorporate comorbidity management into the care of MS?
    Neurology. 2020;95:193-194.
    >> Share

  88. SALTER A, Kowalec K, Fitzgerald KC, Cutter G, et al
    Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial.
    Neurology. 2020;95:e446-e456.
    >> Share

    July 2020
  89. BAR-OR A, Calkwood JC, Chognot C, Evershed J, et al
    Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
    Neurology. 2020 Jul 29. pii: WNL.0000000000010380.
    >> Share

  90. KILLESTEIN J, Du Pasquier R, Hemmer B
    Vaccination in B-cell depleted MS patients.
    Neurology. 2020 Jul 29. pii: WNL.0000000000010378.
    >> Share

  91. VILLOSLADA P, Sanchez-Dalmau B, Galetta S
    Optical coherence tomography: A useful tool for identifying subclinical optic neuropathy in diagnosing multiple sclerosis.
    Neurology. 2020 Jul 28. pii: WNL.0000000000009840.
    >> Share

  92. HAUSER SL, Kappos L, Arnold DL, Bar-Or A, et al
    Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
    Neurology. 2020 Jul 20. pii: WNL.0000000000010376.
    >> Share

  93. SANTORO JD, Waltz M, Aaen G, Belman A, et al
    Pediatric Multiple Sclerosis Severity Score in a Large U.S. Cohort.
    Neurology. 2020 Jul 20. pii: WNL.0000000000010414.
    >> Share

  94. KAPOOR R, Smith KE, Allegretta M, Arnold DL, et al
    Serum neurofilament light as a biomarker in progressive multiple sclerosis.
    Neurology. 2020 Jul 16. pii: WNL.0000000000010346.
    >> Share

  95. CHEN JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, et al
    Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder.
    Neurology. 2020;95:e111-e120.
    >> Share

  96. MANISCALCO GT, Mariotto S, Hoftberger R, Capra R, et al
    GABAA receptor autoimmunity after alemtuzumab treatment for multiple sclerosis.
    Neurology. 2020 Jul 10. pii: WNL.0000000000010310.
    >> Share

  97. GIOVANNONI G, Knappertz V, Steinerman JR, Tansy AP, et al
    A randomized, placebo-controlled phase 2 trial of laquinimod in primary progressive multiple sclerosis.
    Neurology. 2020 Jul 10. pii: WNL.0000000000010284.
    >> Share

  98. FERREIRA D, Ferro D, Bastos G, Pinto M, et al
    Teaching NeuroImages: Useless (and restless) hand of Oppenheim in multiple sclerosis.
    Neurology. 2020 Jul 9. pii: WNL.0000000000010261.
    >> Share

  99. BURON MD, Chalmer TA, Sellebjerg F, Barzinji I, et al
    Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
    Neurology. 2020 Jul 7. pii: WNL.0000000000010135.
    >> Share

    June 2020
  100. VAN KEMPEN ZLE, Kryscio RJ, Dalla Costa G
    Serum neurofilament light as a prognostic marker for MS disability: Are we there yet?
    Neurology. 2020;94:1013-1014.
    >> Share

  101. DAVION JB, Lopes R, Drumez E, Labreuche J, et al
    Asymptomatic optic nerve lesions: An underestimated cause of silent retinal atrophy in MS.
    Neurology. 2020;94:e2468-e2478.
    >> Share

  102. MARRIE RA, Leavitt VM
    Disease-modifying therapies as cognition-modifying therapies? Treating cognitive impairment in MS.
    Neurology. 2020;94:957-958.
    >> Share

  103. CORREALE J, Marrodan M, Benarroch EE
    What is the role of axonal ion channels in multiple sclerosis?
    Neurology. 2020 Jun 1. pii: WNL.0000000000009754.
    >> Share

    May 2020
  104. LUBLIN FD, Coetzee T, Cohen JA, Marrie RA, et al
    The 2013 clinical course descriptors for multiple sclerosis: A clarification.
    Neurology. 2020 May 29. pii: WNL.0000000000009636.
    >> Share

  105. MANOUCHEHRINIA A, Stridh P, Khademi M, Leppert D, et al
    Plasma neurofilament light levels are associated with the risk of disability in multiple sclerosis.
    Neurology. 2020 May 20. pii: WNL.0000000000009571.
    >> Share

  106. LANDMEYER NC, Burkner PC, Wiendl H, Ruck T, et al
    Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.
    Neurology. 2020 May 19. pii: WNL.0000000000009522.
    >> Share

  107. CORTESE M, Munger KL, Martinez-Lapiscina EH, Barro C, et al
    Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.
    Neurology. 2020;94:e1950-e1960.
    >> Share

    April 2020
  108. ARUN T, Pattison L, Palace J
    Distinguishing neurosarcoidosis from multiple sclerosis based on CSF analysis: A retrospective cohort study.
    Neurology. 2020 Apr 30. pii: WNL.0000000000009491.
    >> Share

  109. LANGER-GOULD A, Smith JB, Albers KB, Xiang AH, et al
    Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort.
    Neurology. 2020 Apr 13. pii: WNL.0000000000009374.
    >> Share

  110. DOBSON R, Mowry EM
    Breastfeeding may reduce postpartum relapse in some women with multiple sclerosis.
    Neurology. 2020 Apr 13. pii: WNL.0000000000009369.
    >> Share

  111. LEAVITT VM
    Neurologic determinism? Key update to an age-old debate.
    Neurology. 2020;94:605-606.
    >> Share

  112. BROWNLEE W, Bourdette D, Broadley S, Killestein J, et al
    Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.
    Neurology. 2020 Apr 2. pii: WNL.0000000000009507.
    >> Share

    March 2020
  113. YEH EA, Sormani MP
    Tracking therapies in MS: More evidence in favor of neurofilament.
    Neurology. 2020;94:465-466.
    >> Share

  114. TINTORE M, Perez-Hoyos S, Otero-Romero S
    Author response: Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.
    Neurology. 2020;94:456-457.
    >> Share

  115. JOKUBAITIS VG, Dobson R
    Reader response: Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.
    Neurology. 2020;94:455-456.
    >> Share

  116. GANESH A, Galetta S
    Editors' note: Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.
    Neurology. 2020;94:455.
    >> Share

  117. AMEZCUA L, Smith JB, Gonzales EG, Haraszti S, et al
    Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis.
    Neurology. 2020 Mar 9. pii: WNL.0000000000009210.
    >> Share


  118. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.
    Neurology. 2020 Mar 2. pii: WNL.0000000000008670.
    >> Share

    February 2020
  119. OBEIDAT AZ, Jassam YN, Hua LH, Cutter G, et al
    Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States.
    Neurology. 2020 Feb 27. pii: WNL.0000000000009096.
    >> Share

  120. BRANDSTADTER R, Ayeni O, Krieger SC, Harel NY, et al
    Detection of subtle gait disturbance and future fall risk in early multiple sclerosis.
    Neurology. 2020 Feb 26. pii: WNL.0000000000008938.
    >> Share

  121. DELCOIGNE B, Manouchehrinia A, Barro C, Benkert P, et al
    Blood neurofilament light levels segregate treatment effects in multiple sclerosis.
    Neurology. 2020 Feb 11. pii: WNL.0000000000009097.
    >> Share

    January 2020
  122. HARTUNG DM, Johnston KA, Geddes J, Bourdette DN, et al
    Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis.
    Neurology. 2020 Jan 15. pii: WNL.0000000000008936.
    >> Share

  123. HARDING K, Zhu F, Alotaibi M, Duggan T, et al
    Multiple cause of death analysis in multiple sclerosis: A population-based study.
    Neurology. 2020 Jan 13. pii: WNL.0000000000008907.
    >> Share

  124. MARRIE RA, O'Mahony J, Maxwell C, Ling V, et al
    Increased mental health care use by mothers of children with multiple sclerosis.
    Neurology. 2020 Jan 9. pii: WNL.0000000000008871.
    >> Share

    December 2019
  125. ROTSTEIN DL, Marrie RA, Maxwell C, Gandhi S, et al
    MS risk in immigrants in the McDonald era: A population-based study in Ontario, Canada.
    Neurology. 2019;93:e2203-e2215.
    >> Share

    November 2019
  126. SAVRANSKY A, Rubstein A, Rios MH, Vergel SL, et al
    Prognostic indicators of improvement with therapeutic plasma exchange in pediatric demyelination.
    Neurology. 2019;93:e2065-e2073.
    >> Share

  127. M HARTUNG D, Alley L, A Johnston K, Bourdette DN, et al
    Qualitative study on the price of drugs for multiple sclerosis: Gaming the system.
    Neurology. 2019 Nov 25. pii: WNL.0000000000008653.
    >> Share

  128. MCKAY KA, Ernstsson O, Manouchehrinia A, Olsson T, et al
    Determinants of quality of life in pediatric- and adult-onset multiple sclerosis.
    Neurology. 2019 Nov 15. pii: WNL.0000000000008667.
    >> Share

  129. WATERS P, Vincent A
    Myelin oligodendrocyte glycoprotein CSF testing needs testing.
    Neurology. 2019;93:871-872.
    >> Share

  130. MARIOTTO S, Gajofatto A, Batzu L, Delogu R, et al
    Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases.
    Neurology. 2019;93:e1867-e1872.
    >> Share

  131. ROCCA MA, Valsasina P, Meani A, Gobbi C, et al
    Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
    Neurology. 2019;93:e1852-e1866.
    >> Share

  132. HUPPERTS R, Smolders J, Vieth R, Holmoy T, et al
    Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon beta-1a.
    Neurology. 2019;93:e1906-e1916.
    >> Share

  133. BINZER S, McKay KA, Brenner P, Hillert J, et al
    Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.
    Neurology. 2019 Nov 8. pii: WNL.0000000000008617.
    >> Share

    October 2019
  134. SORMANI MP, Naismith RT
    Measuring disability in multiple sclerosis: Walking plus much more.
    Neurology. 2019 Oct 22. pii: WNL.0000000000008515.
    >> Share

  135. GOLDMAN MD, LaRocca NG, Rudick RA, Hudson LD, et al
    Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data.
    Neurology. 2019 Oct 22. pii: WNL.0000000000008519.
    >> Share


  136. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;93:769.
    >> Share

  137. RAE-GRANT AD
    Author response: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;93:765.
    >> Share

  138. TRAN KR
    Reader response: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;93:764-765.
    >> Share

  139. GANESH A, Galetta S
    Editors' note: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;93:764.
    >> Share

  140. VAN KEMPEN ZLE, Doesburg D, Dekker I, Lissenberg-Witte BI, et al
    The natalizumab wearing-off effect: End of natalizumab cycle, recurrence of MS symptoms.
    Neurology. 2019;93:e1579-e1586.
    >> Share

  141. CLIFFORD DB, Tyler KL
    Dosing interval of natalizumab in MS: Do good things come to those who wait?
    Neurology. 2019;93:655-656.
    >> Share

  142. RYERSON LZ, Foley J, Chang I, Kister I, et al
    Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
    Neurology. 2019;93:e1452-e1462.
    >> Share

  143. TUR C, Kalincik T, Oh J, Sormani MP, et al
    Head-to-head drug comparisons in multiple sclerosis: Urgent action needed.
    Neurology. 2019 Oct 7. pii: WNL.0000000000008319.
    >> Share

    September 2019
  144. WATANABE M, Nakamura Y, Michalak Z, Isobe N, et al
    Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
    Neurology. 2019;93:e1299-e1311.
    >> Share

  145. WONG YYM, Bruijstens AL, Barro C, Michalak Z, et al
    Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes.
    Neurology. 2019;93:e968-e974.
    >> Share

    August 2019
  146. YEH EA, Graves J
    Vaccination: Not a trigger for MS.
    Neurology. 2019;93:377-378.
    >> Share

  147. SUMOWSKI JF, Muhlert N
    Dalfampridine improves slowed processing speed in MS: Picking up the pace.
    Neurology. 2019;93:325-326.
    >> Share

  148. SECHI E, Keegan BM, Kaufmann TJ, Kantarci OH, et al
    Unilateral motor progression in MS: Association with a critical corticospinal tract lesion.
    Neurology. 2019;93:e628-e634.
    >> Share

  149. ZIVADINOV R, Bergsland N, Hagemeier J, Ramasamy DP, et al
    Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS.
    Neurology. 2019;93:e611-e623.
    >> Share

  150. SNYDER J, Turner L
    Crowdfunding for stem cell-based interventions to treat neurologic diseases and injuries.
    Neurology. 2019;93:252-258.
    >> Share

    July 2019
  151. SCHMIDT M, Westemeier J, Gross D
    The two lives of neurologist Helmut J. Bauer (1914-2008): Renowned MS specialist and National Socialist.
    Neurology. 2019;93:109-113.
    >> Share

    May 2019
  152. WAUBANT E, Banwell B, Wassmer E, Sormani MP, et al
    Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG.
    Neurology. 2019;92:e2538-e2549.
    >> Share

  153. PAPADOPOULOU A, Gaetano L, Pfister A, Altermatt A, et al
    Damage of the lateral geniculate nucleus in MS: Assessing the missing node of the visual pathway.
    Neurology. 2019;92:e2240-e2249.
    >> Share

  154. BLANKENBACH K, Schwab N, Hofner B, Adams O, et al
    Natalizumab-associated progressive multifocal leukoencephalopathy in Germany.
    Neurology. 2019;92:e2232-e2239.
    >> Share

    April 2019
  155. DI LUCA DG, De Leon-Benedetti A, Williamson S, Irving LT, et al
    Teaching Video NeuroImages: A patient with Holmes tremor due to demyelinating lesion of the inferior cerebellar peduncle.
    Neurology. 2019;92:e2179-e2180.
    >> Share

  156. VILLOSLADA P, Green AJ, Galetta S
    Personalizing medical care for MS patients: Monitoring brainstem damage by infrared oculography.
    Neurology. 2019 Apr 19. pii: WNL.0000000000007493.
    >> Share

  157. BURON MD, Chalmer TA, Sellebjerg F, Frederiksen J, et al
    Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study.
    Neurology. 2019;92:e1811-e1820.
    >> Share

  158. MEHTA D, Miller C, Arnold DL, Bame E, et al
    Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
    Neurology. 2019;92:e1724-e1738.
    >> Share

  159. KILLESTEIN J, Reder AT
    Dimethyl fumarate-induced changes in the MS lymphocyte repertoire: No need for subset monitoring.
    Neurology. 2019;92:696-697.
    >> Share

  160. WAUBANT E, Gilmore W
    Mind the gap: Quantifying gender representation as a first step to solve the problem?
    Neurology. 2019;92:698-699.
    >> Share

  161. MCDONNELL GV, Marriott JJ
    Patient-perceived risks of MS DMTs: Problems of communication and risk management?
    Neurology. 2019;92:647-648.
    >> Share

  162. MARRIE RA, Garland A, Schaffer SA, Fransoo R, et al
    Traditional risk factors may not explain increased incidence of myocardial infarction in MS.
    Neurology. 2019;92:e1624-e1633.
    >> Share

    March 2019
  163. WATERS PJ, Komorowski L, Woodhall M, Lederer S, et al
    A multicenter comparison of MOG-IgG cell-based assays.
    Neurology. 2019;92:e1250-e1255.
    >> Share

  164. LAPUCCI C, Saitta L, Bommarito G, Sormani MP, et al
    How much do periventricular lesions assist in distinguishing migraine with aura from CIS?
    Neurology. 2019 Mar 8. pii: WNL.0000000000007266.
    >> Share

  165. CULPEPPER WJ, Marrie RA, Langer-Gould A, Wallin MT, et al
    Validation of an algorithm for identifying MS cases in administrative health claims datasets.
    Neurology. 2019;92:e1016-e1028.
    >> Share

  166. WALLIN MT, Culpepper WJ, Campbell JD, Nelson LM, et al
    The prevalence of MS in the United States: A population-based estimate using health claims data.
    Neurology. 2019;92:e1029-e1040.
    >> Share

  167. KUHLE J, Kropshofer H, Haering DA, Kundu U, et al
    Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.
    Neurology. 2019;92:e1007-e1015.
    >> Share

    February 2019
  168. OH J, Ontaneda D, Azevedo C, Klawiter EC, et al
    Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS.
    Neurology. 2019 Feb 20. pii: WNL.0000000000007099.
    >> Share

  169. KOCH-HENRIKSEN N
    Author response: Incidence of MS has increased markedly over 6 decades in Denmark particularly with late onset and in women.
    Neurology. 2019;92:397.
    >> Share

  170. SAJEDI SA
    Reader response: Incidence of MS has increased markedly over 6 decades in Denmark particularly with late onset and in women.
    Neurology. 2019;92:397.
    >> Share

  171. BENARROCH EE
    Autonomic nervous system and neuroimmune interactions: New insights and clinical implications.
    Neurology. 2019;92:377-385.
    >> Share

  172. DALLA COSTA G, Martinelli V, Sangalli F, Moiola L, et al
    Prognostic value of serum neurofilaments in patients with clinically isolated syndromes.
    Neurology. 2019;92:e733-e741.
    >> Share

  173. XU SC, Kardon RH, Leavitt JA, Flanagan EP, et al
    Optical coherence tomography is highly sensitive in detecting prior optic neuritis.
    Neurology. 2019;92:e527-e535.
    >> Share

    January 2019
  174. BERGER JR, Cree BA, Greenberg B, Hemmer B, et al
    Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment.
    Neurology. 2019;92:151.
    >> Share

  175. LALIVE PH, Roth S, Du Pasquier R
    Reader response: Progressive multifocal leukoencephalopathy after fingolimod treatment.
    Neurology. 2019;92:151.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016